Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges

doi:10.3389/fphar.2024.1419384

科研成果详情

题名	Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges
作者	Yang, Ying; Wang, Xiaojing
发表日期	2024-08-06
发表期刊	FRONTIERS IN PHARMACOLOGY 影响因子和分区
语种	英语
原始文献类型	Review
关键词	metabolic dysfunction-associated steatotic liver disease MASLD nano-drug delivery system NDDS nanocarrier nanoparticle nanoliposome
其他关键词	DE-NOVO LIPOGENESIS ; HEPATIC STEATOSIS ; OXIDATIVE STRESS ; NONALCOHOLIC STEATOHEPATITIS ; SCHISANDRA-CHINENSIS ; CD98 EXPRESSION ; GENE DELIVERY ; INFLAMMATION ; NANOPARTICLES ; INTERLEUKIN-22
摘要	About one-third of the global population suffers from metabolic dysfunction-associated steatotic liver disease (MASLD), but specific treatments for MASLD have long been lacking, primarily due to the unclear etiology of the disease. In addition to lifestyle modifications and weight loss surgery, pharmacotherapy is the most common treatment among MASLD patients, and these drugs typically target the pathogenic factors of MASLD. However, bioavailability, efficacy, and side effects all limit the maximum therapeutic potential of the drugs. With the development of nanomedicine, recent years have seen attempts to combine MASLD pharmacotherapy with nanomaterials, such as liposomes, polymer nanoparticles, micelles, and cocrystals, which effectively improves the water solubility and targeting of the drugs, thereby enhancing therapeutic efficacy and reducing toxic side effects, offering new perspectives and futures for the treatment of MASLD.
资助项目	Natural Science Foundation of Zhejiang Province (China) [LLSSY24H160004]
出版者	FRONTIERS MEDIA SA
ISSN	1663-9812
EISSN	1663-9812
卷号	15
DOI	10.3389/fphar.2024.1419384
页数	18
WOS类目	Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:001293265600001
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	39166109
通讯作者地址	[Wang, Xiaojing]Wenzhou Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Lishui, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/217472
专题	附属第一医院附属第一医院_消化内科其他_附属第五医院（丽水市中心医院）
通讯作者	Wang, Xiaojing
作者单位	Wenzhou Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Lishui, Peoples R China; Lishui Municipal Cent Hosp, Lishui, Peoples R China
第一作者单位	附属第一医院; 附属第五医院（丽水市中心医院）; 消化内科
通讯作者单位	附属第一医院; 消化内科
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Yang, Ying,Wang, Xiaojing. Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges[J]. FRONTIERS IN PHARMACOLOGY,2024,15.
APA	Yang, Ying, & Wang, Xiaojing. (2024). Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges. FRONTIERS IN PHARMACOLOGY, 15.
MLA	Yang, Ying,et al."Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges".FRONTIERS IN PHARMACOLOGY 15(2024).